Plasma based protein profiling for early stage lung cancer diagnosis
AssigneeLung Cancer Proteomics LLC
InventorsCherylle Goebel, Christopher Louden, Thomas C Long
Life of this patent
Estimating the term…
Abstract
The invention provides biomarkers and combinations of biomarkers useful in diagnosing non-small cell lung cancer. Measurements of these biomarkers are inputted into a classification system such as Random Forest to assist in determining the likelihood that an individual has non-small cell lung cancer. Kits comprising agents for detecting the biomarkers and combination of biomarkers, as well as systems that assist in diagnosing non-small cell lung cancer are also provided.
Claims10
A method for assaying a plurality of biomarkers, wherein the method comprises
- obtaining a physiological sample from a subject;
- and
- measuring in the physiological sample a set of biomarkers, wherein the set of biomarkers comprises (i) NSE, CXCL9, CEA, CYFRA-21-1, and (ii) at least 9 biomarkers selected from the group consisting of IL-8, MMP-9, sTNFRII, TNFRI, MMP-7, IL-5, Resistin, IL-10, MPO, MCP-1, GRO-Pan, leptin, MIF, sICAM-1, IL-2, SAA, and PDFG-AB/BB, to produce test data comprising a plurality of biomarker measures.
A method for assaying a plurality of biomarkers, wherein the method comprises
- obtaining a physiological sample from a subject;
- and
- measuring in the physiological sample a set of biomarkers, wherein the set of biomarkers comprises (i) NSE, CXCL9, CEA, CYFRA-21-1, and either sTNFRII or PDFG-AB/BB, and (ii) at least 7 biomarkers selected from the group consisting of IL-8, MMP-9, TNFRI, MMP-7, IL-5, Resistin, IL-10, MPO, MCP-1, GRO-Pan, leptin, MIF, sICAM-1, IL-2, and SAA, to produce test data comprising a plurality of biomarker measures.
A method for assaying a plurality of biomarkers, wherein the method comprises
- obtaining a physiological sample from a subject;
- and
- measuring in the physiological sample a set of biomarkers, wherein the set of biomarkers comprises (i) NSE, CXCL9, CEA, CYFRA-21-1, sTNFRII, PDFG-AB/BB, and (ii) at least 7 biomarkers selected from the group consisting of IL-8, MMP-9, TNFRI, MMP-7, IL-5, Resistin, IL-10, MPO, MCP-1, GRO-Pan, leptin, MIF, sICAM-1, IL-2, and SAA, to produce test data comprising a plurality of biomarker measures.
Dependencies are inferred from the claim text.